^Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer. October 2006, 42 (15): 2530–8. PMID 16930989. doi:10.1016/j.ejca.2006.05.029.
^Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Annals of Oncology. February 2010, 21 (2): 275–82. PMID 19633042. doi:10.1093/annonc/mdp314.